Princeton, N.J.—January 21, 2018 — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the new drug application (NDA) for…Original Article
Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot
